Planning

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

NHS ENGLAND

This public procurement record has 1 release in its history.

Planning

21 Mar 2025 at 08:17

UK2 - Preliminary Market Engagement Notice
Summary of the contracting process

NHS England, a central government public authority based in London, is planning to re-tender its National Framework for Medical Retinal Vascular Treatments. The procurement includes Anti VEG-F and Intravitreal Corticosteroid medicines, covering various conditions such as neovascular age-related macular degeneration, diabetic macular oedema, and non-infectious uveitis. The framework agreement is set to begin on 1 December 2025 and may be renewed up to 31 May 2029. Interested suppliers are invited to participate in virtual 1:1 preliminary market engagement meetings by 11 April 2025 to discuss tender structure and other aspects.

This tender presents an excellent opportunity for pharmaceutical companies specialising in medicinal products, particularly those focusing on ophthalmic treatments, to expand their business within the NHS framework. The procurement is well-suited for small and medium-sized enterprises (SMEs) looking to provide innovative solutions in medical retinal care. With a significant contract value exceeding £1.5 billion, this tender offers substantial growth potential for qualified suppliers capable of delivering high-quality therapeutic products. Interested businesses should prepare to engage in the detailed planning stage to align their offerings with NHS England's requirements and timelines.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Start Free Trial Book a Demo
All Features Pricing

Notice Information

Notice Title

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Notice Description

Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; * neovascular (wet) age-related macular degeneration (AMD) * visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) * proliferative diabetic retinopathy (PDR) * visual impairment due to diabetic macular oedema (DME) * visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy * vision impairment associated with chronic diabetic macular oedema, (DME) * visual impairment due to myopic choroidal neovascularisation (myopic CNV) * retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease * inflammation of the posterior segment of the eye presenting as non-infectious uveitis * prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

Planning Information

NHS England is pleased to invite suppliers to a virtual 1:1 preliminary market engagement meeting in relation to the upcoming re-tender of the Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines Framework. The purpose of the sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, clinical aspects and KPI's. Please contact b.kullootee@nhs.net or michelle.clarke6@nhs.net to register your interest. There will also be a 7 day window for queries to be raised in writing after all sessions have concluded.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-04f707
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/010543-2025
Current Stage
Planning
All Stages
Planning

Procurement Classification

Notice Type
UK2 - Preliminary Market Engagement Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Not Specified
Procurement Method Details
Not specified
Tender Suitability
SME
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

33690000 - Various medicinal products

Notice Value(s)

Tender Value
£1,516,353,164 £1B-£10B
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
21 Mar 202511 months ago
Submission Deadline
Not specified
Future Notice Date
2 Jun 2025Expired
Award Date
Not specified
Contract Period
1 Dec 2025 - 31 May 2027 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Planning
Lots Status
Planning
Awards Status
Not Specified
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS ENGLAND
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Post Town
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
Not specified
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts. 

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-04f707-2025-03-21T08:17:42Z",
    "date": "2025-03-21T08:17:42Z",
    "ocid": "ocds-h6vhtk-04f707",
    "initiationType": "tender",
    "parties": [
        {
            "id": "GB-PPON-PDPT-3135-BWWY",
            "name": "NHS England",
            "identifier": {
                "scheme": "GB-PPON",
                "id": "PDPT-3135-BWWY"
            },
            "address": {
                "streetAddress": "Wellington House, 133-135 Waterloo Rd",
                "locality": "London",
                "postalCode": "SE1 8UG",
                "country": "GB",
                "countryName": "United Kingdom",
                "region": "UKI45"
            },
            "contactPoint": {
                "name": "NHS England",
                "email": "b.kullootee@nhs.net"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.england.nhs.uk/",
                "classifications": [
                    {
                        "scheme": "UK_CA_TYPE",
                        "id": "publicAuthorityCentralGovernment",
                        "description": "Public authority - central government"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-PPON-PDPT-3135-BWWY",
        "name": "NHS England"
    },
    "planning": {
        "milestones": [
            {
                "id": "engagement",
                "type": "engagement",
                "description": "NHS England is pleased to invite suppliers to a virtual 1:1 preliminary market engagement meeting in relation to the upcoming re-tender of the Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines Framework. The purpose of the sessions is to update suppliers regarding timelines and to discuss product details, product launches during the proposed framework period, tender structure, clinical aspects and KPI's. Please contact b.kullootee@nhs.net or michelle.clarke6@nhs.net to register your interest. There will also be a 7 day window for queries to be raised in writing after all sessions have concluded.",
                "dueDate": "2025-04-11T23:59:59+01:00",
                "status": "scheduled"
            }
        ],
        "documents": [
            {
                "id": "010543-2025",
                "documentType": "marketEngagementNotice",
                "noticeType": "UK2",
                "description": "Preliminary market engagement notice on Find a Tender",
                "url": "https://www.find-tender.service.gov.uk/Notice/010543-2025",
                "datePublished": "2025-03-21T08:17:42Z",
                "format": "text/html"
            }
        ]
    },
    "tender": {
        "id": "C346388",
        "legalBasis": {
            "id": "2023/54",
            "scheme": "UKPGA",
            "uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
        },
        "title": "NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025",
        "description": "Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; * neovascular (wet) age-related macular degeneration (AMD) * visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) * proliferative diabetic retinopathy (PDR) * visual impairment due to diabetic macular oedema (DME) * visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy * vision impairment associated with chronic diabetic macular oedema, (DME) * visual impairment due to myopic choroidal neovascularisation (myopic CNV) * retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease * inflammation of the posterior segment of the eye presenting as non-infectious uveitis * prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye",
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "33600000",
                        "description": "Pharmaceutical products"
                    },
                    {
                        "scheme": "CPV",
                        "id": "33690000",
                        "description": "Various medicinal products"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK",
                        "country": "GB",
                        "countryName": "United Kingdom"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "value": {
            "amountGross": 1819623796,
            "amount": 1516353164,
            "currency": "GBP"
        },
        "mainProcurementCategory": "goods",
        "aboveThreshold": true,
        "techniques": {
            "hasFrameworkAgreement": true
        },
        "lots": [
            {
                "id": "1",
                "suitability": {
                    "sme": true
                },
                "contractPeriod": {
                    "startDate": "2025-12-01T00:00:00Z",
                    "endDate": "2027-05-31T23:59:59+01:00",
                    "maxExtentDate": "2029-05-31T23:59:59+01:00"
                },
                "hasRenewal": true,
                "status": "planning"
            }
        ],
        "communication": {
            "futureNoticeDate": "2025-06-02T23:59:59+01:00"
        },
        "status": "planning"
    },
    "language": "en"
}